1 terminated. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
Follow Advanced NSCLC: new trials by email Literature Review of Advanced NSCLC trials Research Report on Advanced NSCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer REGN5093-M114, Cemiplimab - Advanced NSCLC | Phase 1 | Terminated | Regeneron Pharmaceuticals | 30 | 2021-11-09 | 2025-11-03 |
Carcinoma, Non-Small-Cell Lung (1)
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
cemiplimab (1)
United States (1)